Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Spruce Biosciences (SPRB) Operating Income (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Operating Income for 4 consecutive years, with -$11.1 million as the latest value for Q4 2025.

  • Quarterly Operating Income rose 53.89% to -$11.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$36.5 million through Dec 2025, up 34.97% year-over-year, with the annual reading at -$36.5 million for FY2025, 34.97% up from the prior year.
  • Operating Income for Q4 2025 was -$11.1 million at Spruce Biosciences, down from -$8.2 million in the prior quarter.
  • The five-year high for Operating Income was -$2.7 million in Q2 2025, with the low at -$24.1 million in Q4 2024.
  • Average Operating Income over 4 years is -$12.0 million, with a median of -$11.8 million recorded in 2022.
  • The sharpest move saw Operating Income plummeted 115.64% in 2024, then skyrocketed 73.18% in 2025.
  • Over 4 years, Operating Income stood at -$12.1 million in 2022, then grew by 7.81% to -$11.2 million in 2023, then tumbled by 115.64% to -$24.1 million in 2024, then skyrocketed by 53.89% to -$11.1 million in 2025.
  • According to Business Quant data, Operating Income over the past three periods came in at -$11.1 million, -$8.2 million, and -$2.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.